Navigation Links
InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
Date:6/15/2012

TEL AVIV, Israel, June 15, 2012 /PRNewswire/ --

InspireMD, Inc. (OTC BB: NSPR) (the "Company" or "InspireMD"), a medical device company focusing on the development and commercialization of its proprietary stent platform technology for use in patients with Acute Myocardial Infarctions, announced today that Craig Shore, Chief Financial Officer, will present at the Marcum MicroCap Conference on June 20th in New York City. The event is hosted by Marcum LLP, one of the top ten auditors of U.S. public companies.

Presentation Details

  • Date: Wednesday, June 20, 2012
  • Time: 10:30AM
  • Location: The Hudson Suite at The Roosevelt Hotel, 45 East 45th Street, New York, NY

Presenting on behalf of InspireMD will be Craig Shore, CFO.

About the Marcum Microcap Conference

The Marcum MicroCap Conference is dedicated to introducing investors to the very best, undiscovered companies under $500 million in market capitalization.  The event is targeted at top fund managers and qualified high net worth investors who focus on small cap equities. More than 500 participants are expected this year, including institutional investors, mutual funds, hedge funds, wealth managers, and family offices. Industries featured include Life Sciences, Technology, Media & Telecom, Social Media & Internet, Consumer, Metals & Mining Industrials and Energy. The conference will also include panel discussions focused on issues that are of key interest to the financial community involved with micro and small-cap growth companies. Marcum LLP is one of the largest independent public accounting and advisory services firms in the U.S.The event is being co-hosted by CCG Investor Relations, a global investor relations consulting firm.

The conference is free to attend for qualified investors. For full event details and registration information, please click here:

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

4

GOOD

Page: 1 2 3 4

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
4. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
5. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
6. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
7. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
8. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
9. Interim results of VITOBA™ (VImpaT® added to One Baseline AED) Study Presented at the 64th Annual Meeting of the American Academy of Neurology
10. Hospira to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
11. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... -- The new 13-valent pneumococcal conjugate vaccine (PCV13) appears ... prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), ... Vaccine. The U.S. Food and Drug Administration ... series of trials. These trials found that PCV13, which ... the previously used PCV7, did not increase the risk ...
(Date:5/22/2013)... , 22. Mai 2013 Kepner-Tregoe ... Beratung, gab heute bekannt, dass der Veteran ... , zum Hauptgeschäftsführer ernannt wurde. Geraghty,s ... Industriebereich wo er zahlreiche Führungspositionen bei Fertigungsunternehmen ... Baxter an, der als Kepner-Tregoe Hauptgeschäftsführer gedient ...
(Date:5/22/2013)... May 22, 2013  MGT Capital Investments, Inc. (NYSE ... at the Second Annual Marcum LLP MicroCap Conference on ... City at the Grand Hyatt Hotel.  ... Officer, will update investors and answer questions. ... presentation is scheduled to begin at 9:30 a.m. EDT.  ...
Breaking Medicine Technology:Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 2Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 3Kaiser Permanente Study Finds New Pneumococcal Vaccine Appears to be as Safe as Previously Used Vaccine 4Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 2Kepner-Tregoe, Inc. befördert Chris Geraghty zum Hauptgeschäftsführer 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4
... The bio-pharmaceutical marketplace - and the Oncology therapeutic ... new medicines and technologies create valuable market opportunities. ... organizations with new Oncology products are scrutinizing their ... Commercial executives in the Oncology therapeutic area make ...
... 28 bioMerieux - a world leader in the ... announced the U.S. launch of chromID MRSA, a simple ... product recently received FDA 510(k) clearance for the detection ... high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.(1) The current ...
Cached Medicine Technology:Educating the Marketplace to Support Successful Oncology Product Launches 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 2bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 3bioMerieux Adds Methicillin-resistant Staphylococcus aureus (MRSA) Screening Tool to its Arsenal 4
(Date:5/22/2013)... 2013 Spinal Elements, an innovative ... in Carlsbad to 3115 Melrose Drive, Suite 200, ... company’s continued and projected growth and has expanded ... feet to over 40,000 square feet. , ... indicated, “Our investment in these state-of-the-art facilities will ...
(Date:5/22/2013)... Lawrenceville, NJ and Los Angeles, CA (PRWEB) May 22, ... chairman of the board, The J. M. Smucker Company, ... GS1 Lifetime Achievement Awards yesterday at the GS1 General ... Los Angeles, California. Mr. Smucker and Mr. Wegman were ... adoption of GS1 Standards - the most broadly used ...
(Date:5/22/2013)... -- Children who are physically, sexually or emotionally abused ... in life, a new review suggests. British researchers ... to be obese as adults. They concluded that child ... for obesity. "We found that being maltreated as ... adult life," study author Dr. Andrea Danese, a child ...
(Date:5/22/2013)... p53 turns off cancer. However, when existing drugs boost p53, only ... study published in the journal Cell Reports shows how: ... more of the protein p21 than the protein PUMA; tumors that ... the current study shows a handful of genes that control this ... mutated cancer genes. Tumors turn it off and then they can ...
(Date:5/22/2013)... May 22, 2013 The new 13-valent pneumococcal conjugate ... previous version used prior to 2010, the 7-valent pneumococcal ... published today in Vaccine . , The U.S. ... in 2010 after a series of trials. These trials ... of pneumococcal types than the previously used PCV7, did ...
Breaking Medicine News(10 mins):Health News:Spinal Elements®, Inc. Relocates Corporate Headquarters in Carlsbad 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 2Health News:Tim Smucker and Danny Wegman Honored With GS1 Lifetime Achievement Awards 3Health News:Abused Children at Risk for Obesity as Adults: Study 2Health News:Study details genes that control whether tumors adapt or die when faced with p53 activating drugs 2Health News:Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine 2
... Inc. (Amex:,ULU) announced today that Ronald A. Ahrens has ... Mr. Ahrens has been an advisor to Merck ... of Merck Consumer Healthcare Group Worldwide.,He had previously served ... From 1985 to 1990 Mr. Ahrens was Consumer,Group President, ...
... 23 The American Society of,Transplantation (AST) recently ... Award, to Richard N. Fine, M.D. at the,American ... a,senior investigator whose lifelong work has advanced the ... the field and the,AST have been broad and ...
... clot-busting tPA, researchers say , , MONDAY, June 23 (HealthDay ... boost stroke patients, survival, new research suggests. , Gleevec, ... as chronic myelogenous leukemia (CML), will be tested to ... the side effects of the clot-dissolving drug tissue plasminogen ...
... and Public Health Experts to Raise Public ... Awareness Via Mobile Media, ... HIV testing is getting out to the general public, thanks to,the ... most reliable wireless voice and data network,announced today its continued effort ...
... 23 Boston Scientific,Corporation (NYSE: BSX ) today ... will help service veterans and the active armed forces,better ... has recently,passed the Veterans Mental Health Improvements Act, which ... originally introduced,by Senator Daniel Akaka (D-HI). The bill calls ...
... Therapeutic Vaccines for Infectious ... Diseases, ... on emerging understanding of the human immune system,today announced the closing of ... Partners, The Column Group and Versant,Ventures. The Column Group initially incubated the ...
Cached Medicine News:Health News:ULURU Inc. Announces the Appointment of Ronald A. Ahrens to the Board of Directors 2Health News:AST Awards Richard N. Fine, M.D. 2008 Ernest Hodge Distinguished Achievement Award 2Health News:Cancer Drug Gleevec Could Fight Stroke 2Health News:Cancer Drug Gleevec Could Fight Stroke 3Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 2Health News:Verizon Wireless Continues Support of National HIV Testing Awareness Campaign 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 2Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 3Health News:Boston Scientific Welcomes Progress on Pain Care Legislation 4Health News:Immune Design Announces $18 Million Series A Financing 2Health News:Immune Design Announces $18 Million Series A Financing 3
... Oximeter with SAC (Serial Autocorrelation) Technology uses ... extract SpO 2 , pulse strength, and ... This cost-effective compact monitor incorporates clinical, ... features, and a data log or trend ...
... Autocorr Plus, the fourth in the ... pulse oximeter/ECG/Respiration Monitor, with 3 or ... oximetry with SAC (Serial Autocorrelation) technology, ... screen display provides two user configurable ...
... The BCI 3180 Pulse Oximeter is a ... SpO 2 pulse rate and pulse ... adult. This AC or battery powered ... low alarm limits and up to 30 ...
... ReZoom intraocular lens is a second-generation refractive ... with greater independence from glasses than monofocal ... a range of vision that monfocals cannot ... technology distributes light over five optic zones ...
Medicine Products: